EMA says disclosure policy 'will not impinge on IP rights'
This article was originally published in SRA
The European Medicines Agency's new policy on clinical trial data disclosure will ensure transparency in the interests of public health without impinging on a company's intellectual property rights1. So says the agency in publishing the final advice from its five cross-sector groups that have been looking at the scientific, technical, legal and ethical issues surrounding this vexed and controversial topic.
You may also be interested in...
A project is about to begin to understand the factors that influence marketing decisions in the various EU member states.
EU trade expert Hervé Jouanjean considers the reasoning behind the EU’s vaccine procurement approach and Italy's decision to block exports of AstraZeneca's COVID-19 vaccine.
Coronavirus Notebook: Italy Makes First Use Of EU’s Vaccine Export Control System, More Regulators Issue Guidance On Variants
Ukraine has established a system for issuing emergency use authorizations for COVID-19 vaccines that recognizes authorizations granted by other world regulators.